Histone deacetylase inhibitors
US7795304B2 · kind B2 · utility
1Cited by
4References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2005 |
| Grant date | Sep 14, 2010 |
| Priority date | — |
| Expiry date | Jan 18, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D277/46
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to hydroxamic acid derivatives having carbamate linkage with the structural formulathat are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous systems (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.